老年非霍奇金淋巴瘤患者潜在不适当用药与生存率降低及毒性增加相关。
Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
作者信息
Lin Richard J, Ma Helen, Guo Robin, Troxel Andrea B, Diefenbach Catherine S
机构信息
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Division of Hematology and Medical Oncology, Laura & Isaac Perlmutter Cancer Center at New York University Langone Medical Center, New York, NY, USA.
出版信息
Br J Haematol. 2018 Jan;180(2):267-270. doi: 10.1111/bjh.15027. Epub 2017 Nov 16.
Abstract
Survival outcomes for elderly lymphoma patients are disproportionally inferior to those of younger patients. We examined medication usage at diagnosis for 171 elderly patients (median age 70 years) with aggressive non-Hodgkin lymphoma treated between 2009 and 2014. At least one potentially inappropriate medication was used in 47% of patients according to the Beers Criteria, 59% experienced treatment delays and/or dose reduction and 65% experienced ≥ grade 3 treatment-related toxicities. We report here for the first time that potentially inappropriate medication use was associated with reduced progression-free survival and overall survival, and increased ≥ grade 3 treatment-related toxicities in multivariate analysis.
摘要
老年淋巴瘤患者的生存结果相较于年轻患者要差得多。我们研究了2009年至2014年间接受治疗的171例老年（中位年龄70岁）侵袭性非霍奇金淋巴瘤患者在诊断时的用药情况。根据Beers标准，47%的患者至少使用了一种潜在不适当药物，59%的患者经历了治疗延迟和/或剂量减少，65%的患者经历了≥3级治疗相关毒性。我们首次在此报告，在多变量分析中，潜在不适当药物的使用与无进展生存期和总生存期缩短以及≥3级治疗相关毒性增加有关。
相似文献
1
Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
Br J Haematol. 2018 Jan;180(2):267-270. doi: 10.1111/bjh.15027. Epub 2017 Nov 16.
2
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).
J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.
3
Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome.
Ann Oncol. 2008 Apr;19(4):774-9. doi: 10.1093/annonc/mdm563. Epub 2007 Dec 6.
4
Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma.
Oncologist. 2021 Nov;26(11):965-973. doi: 10.1002/onco.13915. Epub 2021 Aug 12.
5
Obese non-Hodgkin lymphoma patients tolerate full uncapped doses of chemotherapy with no increase in toxicity, and a similar survival to that seen in nonobese patients.
Leuk Lymphoma. 2016 Nov;57(11):2584-92. doi: 10.3109/10428194.2016.1151508. Epub 2016 Mar 4.
6
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
7
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
Ann Oncol. 2015 May;26(5):958-966. doi: 10.1093/annonc/mdv036. Epub 2015 Jan 28.
8
MTX-HOPE is a low-dose salvage chemotherapy for aged patients with relapsed or refractory non-Hodgkin lymphoma.
J Clin Exp Hematop. 2021 Mar 18;61(1):22-28. doi: 10.3960/jslrt.20051. Epub 2021 Feb 6.
9
Potentially inappropriate medication use in older patients with breast and colorectal cancer.
Cancer. 2018 Jul 15;124(14):3000-3007. doi: 10.1002/cncr.31403. Epub 2018 Apr 24.
10
[Prognostic impact of anthracyclines in the treatment of aggressive lymphoma in patients over 70 years].
Med Clin (Barc). 2015 Jun 22;144(12):544-7. doi: 10.1016/j.medcli.2014.04.026. Epub 2014 Aug 8.
引用本文的文献
1
Association of potentially inappropriate medications with prognosis among older patients with non-small cell lung cancer.
BMC Geriatr. 2024 Jun 25;24(1):550. doi: 10.1186/s12877-024-05138-3.
2
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers.
J Natl Compr Canc Netw. 2022 Aug;20(8):915-923.e5. doi: 10.6004/jnccn.2022.7033.
3
Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients.
Biol Blood Marrow Transplant. 2020 Dec;26(12):2329-2334. doi: 10.1016/j.bbmt.2020.08.031. Epub 2020 Sep 10.
4
Prevalence and effects of polypharmacy on overall survival in acute myeloid leukemia.
Leuk Lymphoma. 2020 Jul;61(7):1702-1708. doi: 10.1080/10428194.2020.1737687. Epub 2020 Mar 11.
5
Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer.
Res Social Adm Pharm. 2020 Oct;16(10):1459-1471. doi: 10.1016/j.sapharm.2019.12.018. Epub 2019 Dec 26.
6
Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis.
Oncologist. 2020 Jan;25(1):e94-e108. doi: 10.1634/theoncologist.2019-0406. Epub 2019 Sep 30.
7
Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults.
Blood Adv. 2019 Jan 8;3(1):12-20. doi: 10.1182/bloodadvances.2018028241.
本文引用的文献
1
Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma.
Blood. 2017 Nov 16;130(20):2180-2185. doi: 10.1182/blood-2017-05-736975. Epub 2017 Aug 16.
2
Diffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.
Expert Rev Hematol. 2017 Apr;10(4):289-297. doi: 10.1080/17474086.2017.1305264. Epub 2017 Mar 27.
3
Polypharmacy and potentially inappropriate medication use in geriatric oncology.
J Geriatr Oncol. 2016 Sep;7(5):346-53. doi: 10.1016/j.jgo.2016.07.010. Epub 2016 Aug 3.
4
Chemotherapy-related cognitive impairment in older patients with cancer.
J Geriatr Oncol. 2016 Jul;7(4):270-80. doi: 10.1016/j.jgo.2016.04.008. Epub 2016 Jul 5.
5
Comprehensive geriatric assessment in elderly patients with newly diagnosed aggressive non-Hodgkin lymphoma treated with multi-agent chemotherapy.
J Geriatr Oncol. 2015 Nov;6(6):470-8. doi: 10.1016/j.jgo.2015.10.183. Epub 2015 Oct 27.
6
American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.
J Am Geriatr Soc. 2015 Nov;63(11):2227-46. doi: 10.1111/jgs.13702. Epub 2015 Oct 8.
7
Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer.
J Clin Oncol. 2015 May 1;33(13):1453-9. doi: 10.1200/JCO.2014.58.7550. Epub 2015 Mar 23.
8
Reducing inappropriate polypharmacy: the process of deprescribing.
JAMA Intern Med. 2015 May;175(5):827-34. doi: 10.1001/jamainternmed.2015.0324.
9
Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review.
Expert Rev Hematol. 2015 Jun;8(3):329-41. doi: 10.1586/17474086.2015.1024650. Epub 2015 Mar 16.
10
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary.
Ann Oncol. 2015 Jun;26(6):1058-1068. doi: 10.1093/annonc/mdv018. Epub 2015 Jan 29.
Zotero 插件